CRIZOTINIB (BRD-K78431006)
Overview
- pert_id
- BRD-K78431006
- Name
- crizotinib
- Synonyms
- PF-02341066; S1068
- Collection
- BIOA
- Summary
- PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley.
- MOA
- ALK tyrosine kinase receptor inhibitor
- Target(s)
- ALK, MET
- Indication(s)
- non-small cell lung cancer (NSCLC)
- Phase
- Launched
- Canonical SMILES
- C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl
- InChI key
- InChIKey=KTEIFNKAUNYNJU-GFCCVEGCSA-N
- InChI string
- InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
- Molecular formula
- C21H22Cl2FN5O
- Molecular weight
- 450.337
External links
- PubChem
- 11626560
- Wikipedia
- http://en.wikipedia.org/wiki/Crizotinib
- SEP-L1000
- BRD-K78431006
Predicted MOAs
| MOA | Probability |
|---|---|
| Aurora kinase inhibitor | 0.2843 |
| EGFR inhibitor | 0.2306 |
| dopamine receptor antagonist | 0.1279 |
| adrenergic receptor antagonist | 0.0766 |
| histamine receptor antagonist | 0.0256 |
| calcium channel blocker | 0.0237 |
| HSP inhibitor | 0.0225 |
| CDK inhibitor | 0.0205 |
| tubulin polymerization inhibitor | 0.0196 |
| PI3K inhibitor | 0.0161 |
Chemical structure
Diagnoses (based on Mount Sinai EHR)
Top diagnoses associated with crizotinib:
Co-prescribed Drugs (based on Mount Sinai EHR)
Top coprescribed drugs of crizotinib:
Age Distribution (based on Mount Sinai EHR)
Probability distribution for the prescription of crizotinib across different ages: